Therapeutic response to asthma medications: genotype predictors.
Asthma is a major social and economic burden. Studies have shown that genetic polymorphisms can influence drug efficacy and/or toxicity. The understanding of the pharmacogenetics of asthma will allow therapeutic regimens to be tailored on an individual basis. It is hoped that linkage and association studies will define new therapeutic targets for asthma but until then, studies have focused on improving response to beta(2)-adrenoceptor agonist and leukotriene modifier therapy. Genetic polymorphism may account for interindividual differences in toxicity and efficacy of asthma medications. To date, single nucleotide polymorphism and limited haplotype analysis have provided inconclusive evidence as to how genotype predictors can be used to optimize current asthma therapies based on each patient's genetic profile.
Wallace
Alison M
AM
University of British Columbia, James Hogg iCapture Centre, St Paul's Hospital, Vancouver, British Columbia, Canada.
Sandford
Andrew J
AJ
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000235:genetics*; D002874:Chromosome Mapping; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D049669:History, 16th Century; D006801:Humans; D015289:Leukotrienes / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide
D000318:Adrenergic beta-Agonists; D015289:Leukotrienes